Furthermore, although IL-6, IL-8, IL-17, and C-reactive protein have been shown to be the major cytokines that cause immune-related adverse events in response to cancer immunotherapy and are downstream of IL-1, blockade of the IL-1 pathway to suppress immunotherapy-mediated toxicity has not been explored. This evidence concerns the gene IL17A and cancer.